HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: A systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2285-2295

  Karlsen, Nikoline S ^a   Karlsen, Mona A ^a,b   Hogdall, Claus K ^b   Hogdall, Estrid V S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

BENIGN TUMOR; CANCER RISK; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; KIDNEY FUNCTION; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURA EFFUSION; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SMOKING; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; BLOOD; CHEMISTRY; FEMALE; FEMALE GENITAL SYSTEM; MALE; MALE GENITAL SYSTEM; METABOLISM; NEOPLASM; PATHOLOGY;

FEMALE; GENITALIA, FEMALE; GENITALIA, MALE; HEALTHY VOLUNTEERS; HUMANS; MALE; NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920127931     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0447     Document Type: Review

References (60)

1. Clauss A, Lilja H, Lundwall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 2002;368:233-42.
2. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45:350-7.
3. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998;3:86-95.
4. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700.
5. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
6. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.
7. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-73.
8. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006;7:61.
9. Georgakopoulos P, Mehmood S, Akalin A, Shroyer KR. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int J Gynecol Pathol 2012;31:517-23.
10. O'Neal RL, Nam KT, Lafleur BJ, Barlow B, Nozaki K, Lee HJ, et al. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol 2013;44:734-42.
11. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
12. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006;7:167-74.
13. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-44.
14. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108: 402-8.
15. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205:358-6.
16. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2012;127:379-83.
17. FDA [homepage on the Internet]. U.S. Food and Drug Administration. [updated 2014 Aug 11; cited 2014 Aug 12]. Available from: http://fda.gov.
18. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR - how well do they correlate? BMC Genomics 2005;6:59.
19. Fujirebio Diagnostics [homepage on the Internet]. HE4 EIA-Instructions for Use [24 pages]; c2008-06 [cited 2014 Aug 12]. Available from: http://www.fdi.com/documents/products/inserts/eia/HE4%20EIA%20404-10US%202008-06%20%20F5908%20r1%20r0%20(3).pdf.
20. Abbott Diagnostics [homepage on the Internet]. HE4 and CA125 Information [about 4 screens]. [updated 2014; cited 2014 Aug 12]. Available from: https://www.abbottdiagnostics.com/en-int/HE4-CA125.
21. Bolstad N, Oijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol 2012;33:141-8.
22. Sandhu N, Karlsen MA, Hogdall C, Laursen IA, Christensen IJ, Hogdall EV. Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. Scand J Clin Lab Invest. 2014 Apr 13. [Epub ahead of print].
23. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29: 365-71.
24. Minimum Information About a Microarray Experiment- MIAME FGED Society; 2010. (Cited 2014 Aug 12.) Available from: http://www.mged.org/Workgroups/MIAME/miame.html.
25. Yamashita S, Tokuishi K, Hashimoto T, Moroga T, Kamei M, Ono K, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011;32:265-71.
26. Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 2012;33:1141-9.
27. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008;134:511-22.
28. Hofman VJ, Moreilhon C, Brest PD, Lassalle S, Le BK, Sicard D, et al. Gene expression profiling in human gastric mucosa infected with Helicobacter pylori. Mod Pathol 2007;20:974-89.
29. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011;104:1418-25.
30. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
31. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
32. Kamei M, Yamashita S, Tokuishi K, Hashioto T, Moroga T, Suehiro S, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res 2010;30: 4779-83.
33. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-26.
34. Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2087-94.
35. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012;50:2181-8.
36. Mokhtar N, Thevarajah M, Ma N, M I. Human epididymis protein 4 reference intervals in a multiethnic asian women population. Asian Pac J Cancer Prev 2012;13:6391-5.
37. Nagy B, Bhattoa HP, Steiber Z, Csoban M, Szilasi M, Mehes G, et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med. 2014 May 15. [Epub ahead of print].
38. Yang J, Sa M, Huang M, Yang J, Xiang Z, Liu B, et al. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay. Clin Biochem 2013;46:1705-8.
39. Hallamaa M, Suvitie P, Huhtinen K, Matomaki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol 2012;125:667-72.
40. Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010;31:411-5.
41. Nagy B Jr, Krasznai ZT, Balla H, Csoban M, Antal-Szalmas P, Hernadi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem 2012;49:377-80.
42. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011;44:884-8.
43. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9.
44. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009;23:331-5.
45. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 2012;206:351-8.
46. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-82.
47. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110: 196-201.
48. Antonsen SL, Hogdall E, Christensen IJ, Lydolph M, Tabor A, Loft JA, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand 2013;92:1313-22.
49. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012;50:2189-98.
50. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol 2013;34:571-6.
51. Ucar EY, Ozkaya AL, Araz O, Akgun M, Meral M, Kaynar H, et al. Serum and bronchial aspiration fluid HE-4 levels in lung cancer. Tumour Biol. 2014 May 31. [Epub ahead of print].
52. Liu W, Yang J, Chi PD, Zheng X, Dai SQ, Chen H, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis 2013;17:1346-53.
53. Elsammak MY, Attia A, Hassan HA, Zaytoun TM, Shorman M, Suleman M. Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion. Tumour Biol 2012;33:1701-7.
54. Xi Z, LinLin M, Ye T. Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal 2009;23:357-61.
55. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98: 172-80.
56. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447-61.
57. Kumpulainen S, Kuoppala T, Leminen A, Penttinen J, Puistola U, Pukkala E, et al. Surgical treatment of ovarian cancer in different hospital categories - a prospective nation-wide study in Finland. Eur J Cancer 2006;42:388-95.
58. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16 (suppl 1):11-7.
59. Fago-Olsen CL, Hogdall C, Kehlet H, Christensen IJ, Ottesen B. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand 2011;90:273-9.
60. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008;54:e1-10.